Truist Maintains Buy Rating on Procept BioRobotics (PRCT) Amid MedTech Sector Rotation

23 hours ago 2

Maham Fatima

Thu, January 8, 2026 astatine 8:42 AM CST 2 min read

Procept BioRobotics Corporation (NASDAQ:PRCT) is 1 of the best up and coming stocks to bargain according to Wall Street. On December 18, Truist expert Richard Newitter lowered the firm’s terms people connected Procept BioRobotics to $47 from $50 portion keeping a Buy standing connected the shares arsenic portion of a 2026 MedTech assemblage preview. Although the steadfast is much optimistic astir the manufacture owed to charismatic valuations, it cautioned that MedTech mightiness enactment arsenic a root of funds alternatively than a superior destination for caller capital. Truist expressed a penchant for companies with circumstantial catalysts susceptible of driving semipermanent gross maturation and those suffering from unpopular short-term marketplace narratives.

On December 12, the institution was initiated by UBS expert Danielle Antalffy with a Buy standing and $62 terms target. Consultations with cardinal sentiment leaders person supported the firm’s assurance successful the company’s utilization maturation done 2026 and 2027. The steadfast believes that the marketplace is presently overlooking respective halfway strengths: Procept’s initiatives to summation usage crossed its existent hardware, the immense imaginable for caller strategy placements successful untapped markets, and the borderline maturation expected from a much profitable merchandise mix.

Truist Maintains Buy Rating connected Procept BioRobotics (PRCT) Amid MedTech Sector Rotation

Earlier connected December 8, Bank of America besides downgraded Procept BioRobotics Corporation (NASDAQ:PRCT) to Neutral from Buy with a terms people of $38, which was brought down from $55. While Procept’s aquablation tech holds important marketplace imaginable for treating benign prostatic hyperplasia, BofA warned investors that slowing utilization maturation is simply a increasing concern. Although the institution is implementing changes to boost usage, these adjustments whitethorn origin short-term operational friction. The steadfast concluded that the simultaneous slowdown successful some strategy income and process measurement makes it hard to consciousness assured astir the stock’s imaginable for near-term growth.

Procept BioRobotics Corporation (NASDAQ:PRCT) is simply a surgical robotics institution that develops transformative solutions successful urology successful the US and internationally.

While we admit the imaginable of PRCT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.